Action Statement Profile KAS 4

Aggregate evidence qualityD (expert consensus).
BenefitPotential for improved metabolic control, improved potential for prevention of hypoglycemia, decreased long-term complications.
HarmPatient discomfort, cost of materials.
Benefits-harms assessmentBenefit over harm.
Value judgmentsDespite lack of evidence, there were general committee perceptions that patient safety concerns related to insulin use or clinical status outweighed any risks from monitoring.
Role of patient preferencesModerate to low; recommendation driven primarily by safety concerns.
ExclusionsNone.
Intentional vaguenessIntentional vagueness in the recommendation about specific approaches attributable to lack of evidence and the need to individualize treatment.
Policy levelOption.